GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stemline Therapeutics Inc (NAS:STML) » Definitions » Profitability Rank

Stemline Therapeutics (Stemline Therapeutics) Profitability Rank : 0 (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Stemline Therapeutics Profitability Rank?

Stemline Therapeutics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Stemline Therapeutics's Operating Margin % for the quarter that ended in Mar. 2020 was -246.29%. As of today, Stemline Therapeutics's Piotroski F-Score is 0.


Competitive Comparison of Stemline Therapeutics's Profitability Rank

For the Biotechnology subindustry, Stemline Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stemline Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stemline Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Stemline Therapeutics's Profitability Rank falls into.



Stemline Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Stemline Therapeutics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Stemline Therapeutics's Operating Margin % for the quarter that ended in Mar. 2020 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2020 ) / Revenue (Q: Mar. 2020 )
=-21.853 / 8.873
=-246.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Stemline Therapeutics has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Stemline Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Stemline Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Stemline Therapeutics (Stemline Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an immunotherapy). The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.
Executives
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Kenneth Hoberman officer: Chief Operating Officer 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Alan S Forman director 55 WHITNEY AVENUE, 5TH FLOOR, NEW HAVEN CT 06511
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Eric K Rowinsky officer: Chief Medical Officer IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014